VANTAA, Finland - Thursday, September 26th 2013 [ME NewsWire] (BUSINESS WIRE)-- Valimo, the world leader in mobile identity authentication, has joined forces with leading Finnish telecommunications service provider Elisa to enable strong mobile login and end-user authentication for Taltioni, a nationwide health and well-being service. Taltioni is a Finnish health services cooperative promoting an open ecosystem for well-being services, and Elisa’s customer in the project. Elisa’s many years in the mobile service business combined with Valimo’s strong mobile ID expertise allows anytime anywhere access to the Taltioni eHealth offers. With Mobile ID, users can securely log in to their eHealth account and authorize healthcare professionals to link medical applications with their personal information. Patients can store, collect, generate and share information received from healthcare professionals, and also the user-collected data. Taltioni stores the data in a protected data
...
Read more »
|
NEW JERSEY - Wednesday, September 25th 2013 [ME NewsWire] (BUSINESS WIRE)-- JP Errico CEO of electroceutical healthcare company electroCore has spearheaded an overhaul of the companys’ management structure over the last two years. Its top team now better reflects its extensive global ambitions and its culture of professionalism and continuous improvement. JP commented, "We are moving into a period of rapid growth as we start to bring our therapies to market across the globe. To meet this challenge we have strengthened our management team with a new focus on the commercialization of our non-invasive vagus nerve stimulation nVNS therapy for headache – cluster and migraine - and to further expand the use of nVNS therapies in gastric motility disorders, bronchoconstriction, epilepsy, depression and anxiety. Initially our commercial efforts are focused on headache in Europe, Australia and Canada where we have regulatory approval. In the US we are presently completing the neces
...
Read more »
|
INGELHEIM, Germany - Wednesday, September 25th 2013 [ME NewsWire] Patients with EGFR mutation positive lung cancer in the European Union can now benefit from a new targeted treatment option, GIOTRIF®, the first irreversible ErbB Family Blocker Afatinib has been shown to delay tumour progression and improve disease related symptoms versus standard chemotherapy1 Afatinib approval marks the first registration of a targeted treatment from Boehringer Ingelheim's oncology portfolio in the EU (BUSINESS WIRE) For non U.S. Media Only Boehringer Ingelheim announced today that the European Commission has granted marketing authorisation for afatinib monotherapy, for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). Afatinib will be marketed in Europe under the brand name GIOTR
...
Read more »
|
Undertakes Novel Genomic "Pre-profiling” Feasibility Study to Examine the Promise of Precision Medicine in Metastatic Colorectal Cancer Patients ME Newswire / Business Wire RESEARCH TRIANGLE PARK, N.C. - Wednesday, September 25th 2013 Quintiles today announced plans to improve the development of biomarker-targeted therapies through a novel approach that promotes the genomic "pre-profiling” of cancer patients. As a first step, Quintiles is undertaking a study with the participation of US Oncology Research, supported by McKesson Specialty Health and The US Oncology Network, to explore the operational feasibility and clinical benefits of an upfront approach to the genomic profiling of tumors from metastatic colorectal cancer (mCRC) patients. The study will investigate how pre-profiling and genomic sequencing data may support physician treatment decisions, including the identification of appropriate clinical trials for patients. "Today, the industry’s approach
...
Read more »
|
Dubai, United Arab Emirates - Tuesday, September 24th 2013 [ME NewsWire] Thuraya Telecommunications Company, a leading Mobile Satellite Services operator today announced that Randy C. Roberts has joined the Company as Vice President of Innovation. In the newly created role, Roberts will oversee product development, product management and solutions engineering. Roberts will report to Samer Halawi, Chief Executive Officer of Thuraya and will serve as a member of the Company’s Executive Team. "I am pleased to welcome Randy Roberts as Vice President of Innovation,” said Halawi. "His extensive experience in product development and management with leading handset OEMs will be a strong asset for Thuraya as we drive new product innovation and expand our offerings, including the Thuraya SatSleeve to new audiences and new sectors.” Roberts is a seasoned telecommunications executive with over 25 years of experience at leading mobile device manufacturers. He brings to Thuraya
...
Read more »
|
INGELHEIM, Germany and INDIANAPOLIS, US - Tuesday, September 24th 2013 [ME NewsWire] Pooled analysis of trial data showed linagliptin was well tolerated including in the elderly with normal renal function to severe renal impairment The overall incidence of adverse events was similar for linagliptin compared to placebo (BUSINESS WIRE)-- For Non-US and Non-UK Media Poster No. 926 & 986 Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented at the 49th European Association of Diabetes (EASD) Annual Meeting. General safety analysis Findings from a pooled comprehensive analysis of safety data in 22 linagliptin clinical trials with
...
Read more »
|
Pooled data from four Phase III trials presented at the 49th EASD Annual Meeting ME Newswire / Business Wire INGELHEIM, Germany & INDIANAPOLIS, US - Tuesday, September 24th 2013 For Non-US and Non-UK Media Poster No. 943 and 944 Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of pooled efficacy data from four Phase III trials that showed treatment with investigational compound empagliflozin*, a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs, improved glycaemic parameters, body weight and blood pressure, in adults with Type 2 Diabetes (T2D).1 Data from this pooled analysis are being presented at the 49th European Association for the Study of Diabetes (EASD) Annual Meeting. "Management of Type 2 Diabetes in people with elevated cardiovascular risk represents a challenge for physicians” said John E. Gerich, M.D. Professor of Medicine and Physiology, University of Roches
...
Read more »
| |